Stock analysts at LADENBURG THALM/SH SH started coverage on shares of Autonomix Medical (NASDAQ:AMIX – Get Free Report) in a report released on Tuesday, Benzinga reports. The brokerage set a “buy” rating and a $1.40 price target on the stock. LADENBURG THALM/SH SH’s price objective would suggest a potential upside of 92.57% from the stock’s previous close.
Autonomix Medical Trading Up 8.5 %
Shares of AMIX stock traded up $0.06 on Tuesday, reaching $0.73. 1,422,854 shares of the company were exchanged, compared to its average volume of 2,031,304. The company has a quick ratio of 9.27, a current ratio of 9.27 and a debt-to-equity ratio of 0.20. The business has a 50-day moving average price of $0.83 and a 200 day moving average price of $2.09. Autonomix Medical has a 1 year low of $0.51 and a 1 year high of $7.60.
Autonomix Medical (NASDAQ:AMIX – Get Free Report) last posted its earnings results on Tuesday, August 13th. The company reported ($0.14) earnings per share for the quarter.
Autonomix Medical Company Profile
Autonomix Medical, Inc, a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals.
See Also
- Five stocks we like better than Autonomix Medical
- High Flyers: 3 Natural Gas Stocks for March 2022
- 3 Small Cap Stocks That Insiders Are Buying
- How to Calculate Return on Investment (ROI)
- Analysts Forecast Big Upside for Western Digital—Don’t Miss Out
- Are Penny Stocks a Good Fit for Your Portfolio?
- 3 Must-Own Stocks for Bullish Investors in Today’s Market
Receive News & Ratings for Autonomix Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autonomix Medical and related companies with MarketBeat.com's FREE daily email newsletter.